Stocks
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
Top Insiders Stocks
Market Movers
TipRanks 50 Index
Dividend Stocks
AI Stocks
Largest Companies by Market Cap
ETFs
Top ETFs by Upside
Top ETFs by Smart Score
Top Gainers/ Losers/ Active ETFs
Crypto
Bitcoin
Popular
Ethereum
Commodities
Gold
Options
Unusual Options Activity
Popular
Currency
EUR/USD
Ideas
Plans
Research Tools
Trending Stocks
Compare Stocks
Compare ETFs
Trump Dashboard
New
Daily Feeds
Daily Analyst Ratings
Daily Insider Trading Tracker
Calendars
Earnings Calendar
Dividend Calendar
Economic Calendar
IPO Calendar
Stock Splits
Stock Buybacks
Market Holidays
Calculators
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Economic Indicators
Inflation Rate
Unemployment Rate
Class Actions
Tools
Plans
Stock Screener
ETF Screener
Popular
Penny Stock Screener
Technical Analysis Screener
Screeners
Plans
Dividend Center
Best Dividend Stocks
Popular
Best High Yield Dividend Stocks
Dividend Aristocrats
Dividend Stock Comparison
New
Dividend Calculator
Dividend Returns Comparison
Dividend Calendar
Dividends
Plans
My Experts
Top Analysts
Top Financial Bloggers
Top-Performing Corporate Insiders
Top Hedge Fund Managers
Top Research Firms
Top Individual Investors
Top Experts
Plans
Portfolio
Plans
Trending News
More News >
News
Plans
Enterprise Solutions
Plans
Education
Personal Finance
How To Use TipRanks
TipRanks Labs
Webinar Center
Glossary
FAQs
About Us
About TipRanks
Contact Us
Careers
Reviews
Mobile APP
Working with TipRanks
Enterprise Solutions
Advertise with Us
Top Online Brokers
Become an Affiliate
TipRanks News Wire
Follow Us
More
Plans
Plans & Pricing
Plans
TOOLS
Portfolio
Watchlist
Top Insiders Stocks
Popular
Top Stocks
Popular
Market Movers
Compare stocks
Compare ETFs
Notification Center
News
Screeners
Stock Screener
ETF Screener
Popular
Penny Stock Screener
Technical Analysis Screener
Ideas
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
Top Insiders Stocks
Research Tools
Compare Stocks
Compare ETFs
Trending Stocks
Daily Analyst Ratings
Daily Insiders Trades
Dividend Stocks
ETF Center
Top Gainers/losers/active ETFs
Trump Dashboard
New
Calculators
Dividend Calculator
Options Profit Calculator
Dollar Cost Averaging
Compound Interest Calculator
Mortgage Calculator
Auto Loan Calculator
Student Loan Calculator
401k Retirement Calculator
Calendars
Earnings Calendar
Dividend Calendar
Economic Calendar
IPO Calendar
Stock Splits
Stock Buybacks
Market Holidays
Dividends
Dividend Center
Best Dividend Stocks
Popular
Best High Yield Dividend Stocks
Dividend Aristocrats
Dividend Stock Comparison
New
Dividend Calculator
Dividend Returns Comparison
Dividend Calendar
Experts
Top Analysts
Top Financial Bloggers
Top-Performing Corporate Insiders
Top Hedge Fund Managers
Top Research Firms
Top Individual Investors
Market Movers
Top Gainers
Top Losers
Most Active
Premarket
After-hours
Personal Finance
Personal Finance Center
Mortgages
Loans
Investing & Retirement
Spending & Savings
Real Estate
Top Online Brokers
Enterprise Solutions
Plans & Pricing
More
Education
How To Use TipRanks
TipRanks Labs
Webinar Center
Glossary
FAQs
About Us
About TipRanks
Contact Us
Careers
Reviews
Mobile APP
Working with TipRanks
Enterprise Solutions
Top Online Brokers
Become an Affiliate
TipRanks News Wire
Follow Us
STOCKS
SPY
QQQ
AAPL
NVDA
TSLA
AMZN
BABA
Log Out
LRMR
Stock Latest News
Ratings
Positive Outlook for Larimar Therapeutics: Promising Data on Nomlabofusp and Anticipated Catalysts Drive Buy Rating
20h ago
LRMR
Premium
The Fly
Larimar Therapeutics’ nomlabofusp shows therapeutic potential in FA
1d ago
LRMR
Premium
Ratings
Promising Regulatory Progress and Market Potential for Larimar Therapeutics
13d ago
LRMR
Premium
The Fly
Larimar Therapeutics price target lowered to $15 from $17 at Wedbush
15d ago
LRMR
Premium
The Fly
Larimar Therapeutics selloff a buying opportunity, says Citi
15d ago
LRMR
Premium
Company Announcements
Larimar Therapeutics Updates on Nomlabofusp Progress
16d ago
8K
LRMR
Premium
Ratings
Larimar Therapeutics: FDA Guidance Boosts Buy Rating Amid Promising Regulatory Progress
16d ago
LRMR
Premium
Company Announcements
Larimar Therapeutics Receives FDA Guidance for BLA Submission
16d ago
8K
LRMR
Premium
The Fly
Larimar announces FDA safety database recommendations for nomlabofusp BLA
16d ago
LRMR
Premium
The Fly
Larimar to trade down on delayed FDA submission, says JonesResearch
16d ago
LRMR
Premium
Company Announcements
Larimar Therapeutics Holds 2025 Annual Stockholders Meeting
2M ago
8K
LRMR
Premium
Company Announcements
Larimar Therapeutics Advances Nomlabofusp Amid Financial Loss
2M ago
LRMR
Premium
The Fly
Biotech Alert: Searches spiking for these stocks today
2M ago
ATOS
CYCC
Premium
Ratings
Optimistic Buy Rating for Larimar Therapeutics Amid Promising Phase II Study and Regulatory Progress
2M ago
LRMR
Premium
Ratings
Buy Rating for Larimar Therapeutics Driven by Regulatory Progress and FDA Support
2M ago
LRMR
Premium
The Fly
Larimar Therapeutics reports Q1 EPS (46c), consensus (41c)
2M ago
LRMR
Premium
The Fly
Larimar Therapeutics sees cash runway into 2Q26
2M ago
LRMR
Premium
The Fly
Larimar Therapeutics management to meet with Truist
2M ago
LRMR
Premium
Ratings
Promising Outlook for Larimar Therapeutics: Buy Rating on Nomlabofusp’s Potential in Treating Friedreich’s Ataxia
3M ago
LRMR
Premium
Ratings
Promising Developments and Financial Strength Support Buy Rating for Larimar Therapeutics
3M ago
LRMR
Premium
The Fly
Larimar Therapeutics should be bought on weakness, says Citi
4M ago
LRMR
Premium
The Fly
Larimar Therapeutics price target raised to $16 from $15 at H.C. Wainwright
4M ago
LRMR
Show More
Trending
Indices
Stocks
ETFs
Name
Price
Price Change
SPX
S&P 500
DJIA
Dow Jones
NDX
Nasdaq 100
More Trending Stocks >
You need to enable JavaScript to run this app.
